AB Science (LSE:0Q77) - Stock Price, News & Analysis

0Q77 Stock Overview

AB Science S.A., empresa farmacéutica, se dedica a la investigación, desarrollo y comercialización de inhibidores de la proteína cinasa para su uso en medicamentos humanos y veterinarios.

About the company

0Q77 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	1/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Se prevé un crecimiento anual de los ingresos de 10.82%

Los beneficios han crecido 14.8% al año en los últimos 5 años.

Risk Analysis

Tiene unos ingresos inferiores a 1 millón de dólares (€777K)

Cotización muy volátil en los últimos 3 meses

Los accionistas se han diluido en el último año

0Q77 tiene fondos propios negativos.

+ 1 more risk

AB Science S.A. Competitors

Allergy Therapeutics

AIM:AGY

UK£135.8m

Animalcare Group

AIM:ANCR

UK£125.0m

ECO Animal Health Group

AIM:EAH

UK£57.6m

Poolbeg Pharma

AIM:POLB

UK£50.0m

Price History & Performance

Summary of all time highs, changes and price drops for AB Science
Historical stock prices
Current Share Price	€2.26
52 Week High	€6.68
52 Week Low	€1.57
Beta	1.06
1 Month Change	2.04%
3 Month Change	-38.55%
1 Year Change	-60.78%
3 Year Change	-85.35%
5 Year Change	-48.15%
Change since IPO	-82.65%

Recent updates

Shareholder Returns

	0Q77	GB Pharmaceuticals	GB Market
7D	-10.9%	-1.8%	-0.5%
1Y	-60.8%	-4.7%	0.4%

Rentabilidad frente al sector: 0Q77 obtuvo unos resultados inferiores a los del sector UK Pharmaceuticals , que el año pasado arrojó un rendimiento del -5.5%.

Rentabilidad vs. Mercado: 0Q77 obtuvo unos resultados inferiores a los del mercado UK, que fue del -5.3% el año pasado.

Price Volatility

Is 0Q77's price volatile compared to industry and market?
0Q77 volatility
0Q77 Average Weekly Movement	13.1%
Pharmaceuticals Industry Average Movement	8.5%
Market Average Movement	4.9%
10% most volatile stocks in GB Market	11.2%
10% least volatile stocks in GB Market	2.6%

Precio estable de las acciones: 0Q77ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: 0Q77(10%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de los valores de UK.

About the Company

Founded	Employees	CEO	Website
2001	89	Alain Moussy	https://www.ab-science.com

AB Science S.A., empresa farmacéutica, se dedica a la investigación, desarrollo y comercialización de inhibidores de la proteína cinasa para su uso en medicamentos humanos y veterinarios. Su compuesto principal es el masitinib, un inhibidor de la tirosina quinasa que se encuentra en ensayos clínicos de fase III para el tratamiento del cáncer de próstata y de páncreas, la esclerosis lateral amiotrófica, la esclerosis múltiple, el Alzheimer, el asma grave y las enfermedades mastocitósicas, así como en ensayos clínicos de fase II para tratar el Covid-19. La empresa también está desarrollando AB8939, un desestabilizador sintético de microtúbulos para indicaciones hematológicas.

AB Science S.A. Fundamentals Summary

How do AB Science's earnings and revenue compare to its market cap?
0Q77 fundamental statistics
Market cap	€115.41m
Earnings (TTM)	-€16.88m
Revenue (TTM)	€777.00k

148.5x

P/S Ratio

-6.8x

P/E Ratio

Is 0Q77 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0Q77 income statement (TTM)
Revenue	€777.00k
Cost of Revenue	€92.00k
Gross Profit	€685.00k
Other Expenses	€17.57m
Earnings	-€16.88m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

Apr 30, 2024

Earnings per share (EPS)	-0.33
Gross Margin	88.16%
Net Profit Margin	-2,173.10%
Debt/Equity Ratio	-97.2%

How did 0Q77 perform over the long term?

See historical performance and comparison

0Q77 Stock Overview

Rewards

Risk Analysis

AB Science S.A. Competitors

AIM:AGY

UK£135.8m

AIM:ANCR

UK£125.0m

AIM:EAH

UK£57.6m

AIM:POLB

UK£50.0m

Price History & Performance

Recent News & Updates

AB Science Announces Eligibility granted by Health Canada for Reconsideration Request for Masitinib in ALS

AB Science S.A. to Report First Half, 2024 Results on Sep 30, 2024

AB Science Receives Notice of Allowance for European Patent Covering masitinib Until 2036 in the Treatment of mastocytosis

First half 2023 earnings released: €0.22 loss per share (vs €0.15 loss in 1H 2022)

New minor risk - Financial data availability

New minor risk - Financial data availability

Recent updates

AB Science Announces Eligibility granted by Health Canada for Reconsideration Request for Masitinib in ALS

AB Science S.A. to Report First Half, 2024 Results on Sep 30, 2024

AB Science Receives Notice of Allowance for European Patent Covering masitinib Until 2036 in the Treatment of mastocytosis

First half 2023 earnings released: €0.22 loss per share (vs €0.15 loss in 1H 2022)

New minor risk - Financial data availability

New minor risk - Financial data availability

New minor risk - Shareholder dilution

AB Science S.A. Receives Notice of Allowance for European Patent Covering Masitinib in the Treatment of Metastatic Castrate Refractory Prostate Cancer (mCRPC)

Full year 2022 earnings released: €0.29 loss per share (vs €0.30 loss in FY 2021)

AB Science S.A. to Report Fiscal Year 2022 Results on Apr 28, 2023

AB Science S.A. Receives Approval from the U.S. Food and Drug Administration (FDA) to Initiate the Confirmatory Phase 3 Study with Masitinib in the Treatment of Progressive Multiple Sclerosis

AB Science S.A. announced that it expects to receive €15 million in funding from European Investment Bank, Investment Arm

AB Science SA Receives Notice of Deficiency from Health Canada for Masitinib in Treatment of Amyotrophic Lateral Sclerosis

AB Science SA Receives U.S. Food and Drug Administration Authorization to Initiate Confirmatory Phase 3 Clinical Study with Masitinib in the Treatment of Alzheimer’s Disease

AB Science Sa Receives First Agencies Authorizations to Initiate Confirmatory Phase 3 Clinical Study with Masitinib in the Treatment of Alzheimer's Disease

First half 2022 earnings released: EPS: €0 (vs €0.099 loss in 1H 2021)

AB Science SA Announces Positive Recommendation of Data and Safety Monitoring Board to Continue Phase 2 Study Evaluating Antiviral Activity of Masitinib in Covid-19

AB Science Announces That It Has Filed an Application for Conditional Marketing Authorization to EMA for Masitinib in the Treatment of ALS

AB Science SA Announces Publication of Results from its Positive Study of Masitinib in Severe Asthma Uncontrolled by Oral Corticosteroids in the Peer-Reviewed Journal of Asthma and Allergy

AB Science Announces Changes in the Board of Directors

AB Science S.A. Announces Publication of Results from Its Positive Pivotal Phase 3 Trial of Masitinib in Progressive Forms of Multiple Sclerosis in the Peer-Reviewed Journal Neurology® Neuroimmunology & Neuroinflammation

AB Science SA Announces Health Canada Has Granted Authorization to File New Drug Submission for Masitinib in the Treatment of ALS Under the Notice of Compliance with Conditions (NOC/c) Policy

AB Science SA Grants Authorization to Initiate Confirmatory Phase III Trial of Masitinib in Progressive Forms of Multiple Sclerosis by the Swedish Medical Products Agency

AB Science SA Receives Authorization to Initiate Phase II Study in Patients with Severe Mast Cell Activation Syndrome by the French Health Authority (ANSM)

AB Science Announces That It Has Been Granted Authorization to Initiate Confirmatory Phase III Trial of Masitinib in Progressive Forms of Multiple Sclerosis by the French Health Authority (ANSM)

AB Science S.A. Announces Dosing of First Patient in Phase 2 Trial of Masitinib’s Antiviral Activity Against the SARS-CoV-2 (Covid-19) Virus

AB Science Receives FDA Authorization to Initiate Phase 1/Ii Trial of Ab8939 in the Treatment of Acute Myeloid Leukemia

First half 2021 earnings released: €0.099 loss per share (vs €0.23 loss in 1H 2020)

AB Science SA Receives Regulatory Authorization to Commence A Second Phase 2 Covid-19 Study

AB Science S.A. Receives Health Canada Approval Letter to Commence Phase I/II Trial of Ab8939 in the Treatment of Acute Myeloid Leukemia (AML)

AB Science S.A. Receives Authorization to Resume Patient Enrollment in the Phase 2 Masitinib Study of Covid-19

AB Science S.A. Receives New Authorizations to Resume Patient Enrollment in Its Phase 3 Studies of Masitinib

AB Science Announces Results from Masitinib Study Ab12003 in Prostate Cancer Have Been Presented At the 2021 American Urological Association

AB Science SA Announces That It Has Received Second Authorization to Resume Patient Enrollment, in the Phase 3 Study of Masitinib in Mastocytosis

AB Science Announces Receives the First Authorization to Resume Patient Enrollment in the Confirmatory Phase 3 Study of Masitinib (AB19001) in ALS

AB Science Announces the Validation of Its Risk Management Plan by the French National Agency (ANSM) in Order to Restart Patient Enrollment in France

AB Science SA Announces Results from Masitinib Study AB12005 in Pancreatic Cancer Have Been Presented At the 2021 Asco Annual Meeting

AB Science SA Announces Update of Masitinib

AB Science SA Communicates Results from Phase 3 Study Evaluating Masitinib in Prostate Cancer

AB Science Sa Announces Results from Masitinib Study AB12005 in Pancreatic Cancer, Have Been Selected for Presentation at the Upcoming Asco Annual Meeting

Full year 2020 earnings released

AB Science Sa Announces Identification of Two Tissue Biomarkers That Could Potentially Serve as Predictive Biomarkers of Response for Masitinib Treatment

AB Science Announces a New Independent Publication Confirms That Masitinib Has Anti-Vital Activity Against the SARS-CoV-2 Virus in Vitro and Is A Promising Candidate for Treating COVID-19

AB Science S.A. has completed a Follow-on Equity Offering in the amount of €10.50001 million.

AB Science Issues A Corrective Press Release Regarding Adverse Events Information from Study AB09004 Reported on December 16, 2020

AB Science Announces That Phase 2B/3 Study Evaluating Oral in Alzheimer’S Disease Met Its Primary Endpoint

New 90-day high: €14.30

AB Science S.A. Announces That Confirmatory Phase 3 Study AB12005 with Masitinib in First Line Pancreatic Cancer with Pain Was Successful

AB Science S.A. Announces Results from masitinib Study AB07015 in Severe Asthma Have Been Selected for Presentation At an ATS Symposium Held on October 16, 2020

First half earnings released

AB Science SA Presents Phase 2B/3 Study Results in Progressive Multiple Sclerosis at the World's Large Multiple Sclerosis Research Conference

New 90-day high - €12.68

New 90-day high - €9.47

Shareholder Returns

Price Volatility

About the Company

AB Science S.A. Fundamentals Summary

148.5x

-6.8x